AMWL — American Well Corporation

Amwell (AMWL) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $54.9 million, down 18% year-over-year.
• Subscription Revenue: $24.9 million, down 23% year-over-year, primarily due to churn.
• Amwell Medical Group (AMG) Visit Revenue: $28.9 million, up 9% year-over-year, with 382,000 paid visits.
• Gross Profit: $28 million, gross margin at 51%, down from 52.8% in Q1 2025.
• Operating Expenses: $45.4 million, down 31% year-over-year; operating loss improved to $17.4 million from $30.4 million.
• Adjusted EBITDA: Loss of $3.1 million, improved from a loss of $12.2 million in Q1 2025.
• Cash Position: $179 million in cash and investments, with no debt; cash burn reduced to $3.1 million from $19 million last quarter.

2. Strategic Updates and Business Highlights

• Renewed contract with Elevance Health for three years, highlighting confidence in Amwell's platform.
• Significant operational improvements and a focus on a unified digital platform to address customer needs.
• Increased emphasis on AI capabilities, positioning Amwell as an infrastructure provider for AI-driven care.
• The platform is designed to enhance integration and performance measurement across various clinical programs.
• Strong growth in virtual primary care visits (up 57% year-over-year).

3. Forward Guidance and Outlook

• Q2 2026 Revenue Guidance: Expected between $48 million to $52 million; adjusted EBITDA loss projected between $4 million to $2 million.
• Full Year 2026 Revenue Guidance: Reiterated at $195 million to $205 million; adjusted EBITDA loss revised to $16 million to $12 million, improved from previous expectations.
• Confidence in achieving cash flow breakeven by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Total revenue decline of 18% year-over-year and subscription revenue drop of 23% due to churn.
• Challenges in customer adoption of technology due to vendor sprawl and integration difficulties.
• Despite strong demand, customers face hurdles in measuring performance and optimizing member experiences.
• The overall visit volume decreased by 19% year-over-year, reflecting portfolio changes.
• Concerns about the competitive landscape and the need for continuous innovation and customer engagement.

5. Notable Q&A Insights

• Discussions on the Defense Health Agency (DHA) contract renewal indicate confidence in maintaining the relationship, with potential for future expansion into behavioral health services.
• The pipeline is reportedly growing significantly, with expectations of triple-digit growth compared to the previous year, particularly in government contracts.
• Clients are increasingly interested in AI capabilities, though some remain cautious about integrating these features into their existing platforms.
• Management expressed optimism about revenue growth in 2027, driven by new government contracts and improved operational efficiencies.

Overall, Amwell's Q1 2026 results reflect both progress and challenges, with a focus on strategic growth, operational efficiency, and adapting to market demands.